Tags

Type your tag names separated by a space and hit enter

Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C.
Z Gastroenterol. 2003 Oct; 41(10):983-90.ZG

Abstract

OBJECTIVES

Hepatitis A (HAV) and B (HBV) vaccinations are recommended in patients with chronic liver diseases.

METHODS

We prospectively investigated immunogenicity and safety of an accelerated vaccination protocol (0-7-21 days) with the combined hepatitis A/B vaccine (Twinrix(R)) versus the standard vaccination scheme (0-1-6 months) in hepatitis C virus-infected patients versus healthy volunteers.

RESULTS

Local and general symptoms were mostly mild in all groups. One month after completion of the accelerated vaccination or standard vaccination, with the combined hepatitis A/B vaccine anti-HAV seroconversion rates (>33 IU/l) were 89 % and 88 % in HCV-infected patients. Initial HCV-nonresponders developed protective anti-HAV antibodies in 94 % and 96 % after a booster dose. According to the anti-HBs seroprotection rate, HCV-infected patients developed protective anti-HBs titres (>10 IU/l) in 77 % and 82 % of cases one month after the accelerated and the standard vaccination scheme-at month 2 and 7, respectively. This anti-HBs seroprotection rate could even be increased to 84 % and 85 % when initial HCV-infected nonresponders where given a booster dose with the combined hepatitis A/B vaccine. Protective anti-HAV and anti-HBs titers were achieved as early as month 2 after the accelerated vaccination schedule in the majority of HCV-infected patients. Healthy subjects developed protective anti-HAV titers and anti-HBs titers in 100 % and 98 % after the accelerated and standard vaccination protocol.

CONCLUSIONS

This study is the first to have demonstrated that the accelerated combined hepatitis A/B vaccination is both safe and highly immunogenic against HAV and HBV in HCV-infected patients with well compensated liver disease.

Authors+Show Affiliations

Department of Internal Medicine IV, University of Heidelberg, Heidelberg, Germany. birgit_kalinowski@med.uni-heidelberg.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

14562195

Citation

Kallinowski, B, et al. "Immunogenicity of an Accelerated Vaccination Regime With a Combined Hepatitis A/b Vaccine in Patients With Chronic Hepatitis C." Zeitschrift Fur Gastroenterologie, vol. 41, no. 10, 2003, pp. 983-90.
Kallinowski B, Jilg W, Buchholz L, et al. Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C. Z Gastroenterol. 2003;41(10):983-90.
Kallinowski, B., Jilg, W., Buchholz, L., Stremmel, W., & Engler, S. (2003). Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C. Zeitschrift Fur Gastroenterologie, 41(10), 983-90.
Kallinowski B, et al. Immunogenicity of an Accelerated Vaccination Regime With a Combined Hepatitis A/b Vaccine in Patients With Chronic Hepatitis C. Z Gastroenterol. 2003;41(10):983-90. PubMed PMID: 14562195.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity of an accelerated vaccination regime with a combined hepatitis a/b vaccine in patients with chronic hepatitis C. AU - Kallinowski,B, AU - Jilg,W, AU - Buchholz,L, AU - Stremmel,W, AU - Engler,S, PY - 2003/10/17/pubmed PY - 2004/3/18/medline PY - 2003/10/17/entrez SP - 983 EP - 90 JF - Zeitschrift fur Gastroenterologie JO - Z Gastroenterol VL - 41 IS - 10 N2 - OBJECTIVES: Hepatitis A (HAV) and B (HBV) vaccinations are recommended in patients with chronic liver diseases. METHODS: We prospectively investigated immunogenicity and safety of an accelerated vaccination protocol (0-7-21 days) with the combined hepatitis A/B vaccine (Twinrix(R)) versus the standard vaccination scheme (0-1-6 months) in hepatitis C virus-infected patients versus healthy volunteers. RESULTS: Local and general symptoms were mostly mild in all groups. One month after completion of the accelerated vaccination or standard vaccination, with the combined hepatitis A/B vaccine anti-HAV seroconversion rates (>33 IU/l) were 89 % and 88 % in HCV-infected patients. Initial HCV-nonresponders developed protective anti-HAV antibodies in 94 % and 96 % after a booster dose. According to the anti-HBs seroprotection rate, HCV-infected patients developed protective anti-HBs titres (>10 IU/l) in 77 % and 82 % of cases one month after the accelerated and the standard vaccination scheme-at month 2 and 7, respectively. This anti-HBs seroprotection rate could even be increased to 84 % and 85 % when initial HCV-infected nonresponders where given a booster dose with the combined hepatitis A/B vaccine. Protective anti-HAV and anti-HBs titers were achieved as early as month 2 after the accelerated vaccination schedule in the majority of HCV-infected patients. Healthy subjects developed protective anti-HAV titers and anti-HBs titers in 100 % and 98 % after the accelerated and standard vaccination protocol. CONCLUSIONS: This study is the first to have demonstrated that the accelerated combined hepatitis A/B vaccination is both safe and highly immunogenic against HAV and HBV in HCV-infected patients with well compensated liver disease. SN - 0044-2771 UR - https://www.unboundmedicine.com/medline/citation/14562195/Immunogenicity_of_an_accelerated_vaccination_regime_with_a_combined_hepatitis_a/b_vaccine_in_patients_with_chronic_hepatitis_C_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2003-42929 DB - PRIME DP - Unbound Medicine ER -